Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4-T Study: Insulin Regimens in Type 2 Diabetes
NCT00184600Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2004
- Primary completion
- Aug 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Basal Insulin (Detemir), Prandial Insulin (Aspart) and Biphasic Insulin (Aspart 30) (3 arms). Primary endpoint: Glycosylated Haemoglobin at 36 months. Started Nov 2004; status: completed.
02
Drugs
insulin detemirinsulin aspartInsulin aspart + insulin aspart protamine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00184600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00184600.